This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2005;1(1):5-8.

doi: 10.2147/vhrm.1.1.5.58931.

Coxibs: can this class of drugs survive?

Reza Tabrizchi¹

Affiliations

PMID: 17319092
PMCID: PMC1993934
DOI: 10.2147/vhrm.1.1.5.58931

Coxibs: can this class of drugs survive?

Reza Tabrizchi. Vasc Health Risk Manag. 2005.

. 2005;1(1):5-8.

doi: 10.2147/vhrm.1.1.5.58931.

Author

Reza Tabrizchi¹

Affiliation

¹ Division of Basic Medical Sciences, Faculty of Medicine, Memorial University of Newfoundland, St John's, NL, Canada.

PMID: 17319092
PMCID: PMC1993934
DOI: 10.2147/vhrm.1.1.5.58931

No abstract available

PubMed Disclaimer

Similar articles

Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
De Vecchis R, Baldi C, Di Biase G, Ariano C, Cioppa C, Giasi A, Valente L, Cantatrione S. De Vecchis R, et al. Minerva Cardioangiol. 2014 Dec;62(6):437-48. Epub 2014 Jul 16. Minerva Cardioangiol. 2014. PMID: 25029569
COX-2 selective inhibitors and heart health.
Simon LS, White WB. Simon LS, et al. Postgrad Med. 2005 Jan;117(1 Suppl):7-20. doi: 10.3810/pgm.01.2005.suppl40.201. Postgrad Med. 2005. PMID: 19667717 Review.
Clinical use and pharmacological properties of selective COX-2 inhibitors.
Shi S, Klotz U. Shi S, et al. Eur J Clin Pharmacol. 2008 Mar;64(3):233-52. doi: 10.1007/s00228-007-0400-7. Epub 2007 Nov 13. Eur J Clin Pharmacol. 2008. PMID: 17999057 Review.
Lessons to learn from the COX-2 saga. Yes, FDA reforms are needed. And marketing distorts how medications are used. But one moral to the story is that all drugs have risks.
[No authors listed] [No authors listed] Harv Health Lett. 2005 Mar;30(5):1-3. Harv Health Lett. 2005. PMID: 16526110 No abstract available.
[Cardiovascular events: a class effect by COX-2 inhibitors].
Araujo LF, Soeiro Ade M, Fernandes Jde L, Serrano Júnior CV. Araujo LF, et al. Arq Bras Cardiol. 2005 Sep;85(3):222-9. doi: 10.1590/s0066-782x2005001600016. Epub 2005 Sep 29. Arq Bras Cardiol. 2005. PMID: 16200274 Review. Portuguese. No abstract available.

See all similar articles

Cited by

Risk of cardiovascular events and cyclooxygenase-2 inhibitors.
Tabrizchi R. Tabrizchi R. Vasc Health Risk Manag. 2006;2(2):95-6. doi: 10.2147/vhrm.2006.2.2.95. Vasc Health Risk Manag. 2006. PMID: 17319452 Free PMC article. No abstract available.
Ecosinoids and blood vessel structure.
Tabrizchi R. Tabrizchi R. Vasc Health Risk Manag. 2005;1(2):91-2. doi: 10.2147/vhrm.1.2.91.64081. Vasc Health Risk Manag. 2005. PMID: 17315393 Free PMC article. No abstract available.

References

1. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520–8. - PubMed
1. Brock TG, McNish RW, Peters-Golden M. Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2. J Biol Chem. 1999;274:11660–6. - PubMed
1. Catella-Lawson F. Vascular biology of thrombosis. Neurology. 2001;57(Suppl 2):S5–7. - PubMed
1. Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther. 1999;289:735–41. - PubMed
1. Clark DWJ, Layton D, Shakir SAW. Do some inhibitors of COX-2 increase the risk of thromboembolic events? Drug Saf. 2004;27:427–56. - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information